Otsuka’s IV solutions subsidiary, Otsuka Pharmaceutical Factory, is breaking into the North American market with the help of ...

ICU Medical (NASDAQ:ICUI) and Otsuka Pharmaceutical Factory, a unit of Japan’s Otsuka, are launching a joint venture focused ...

Otsuka Holdings will pay ICU Medical an upfront payment of $200 million. The U.S. IV products market has seen ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...

ICU Medical (ICUI) and Otsuka Pharmaceutical Factory, global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint venture to provide additional ...

Otsuka Holdings Co (JP:4578) has released an update. Otsuka Pharmaceutical Factory America, a subsidiary of Otsuka Pharmaceutical Factory, has ...

Aurinia Pharmaceuticals Reports Q3 and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

The bottom half of the list featured Reckitt Benckiser’s Mucinex, AstraZeneca’s Breztri Aerosphere, Otsuka’s Rexulti, ...

USA: An interim analysis of the Phase 3 VISIONARY study revealed that sibeprenlimab achieved a significant and clinically ...

The Suez Canal Economic Zone (SCZone) will establish a dedicated pharmaceutical industry zone covering an area of four ...